Abstract
520 Background: AA treatment may suppress androgens and estrogens that stimulate BCa growth. We conducted a biomarker analysis of circulating tumor cells (CTCs) and formalin-fixed paraffin-embedded tissues (FFPETs) from a phase 2 study of the efficacy and safety of AA in postmenopausal ER+ BCa pts to analyze serum steroid concentrations and identify subgroups with AA sensitivity. Methods: Treatments: AA (1 g/d) + P (5 mg/d) vs AA + P + E (25 mg/d) vs E alone. FFPETs from diagnosis and blood samples collected at baseline, during treatment, and at the end of treatment were used for molecular characterization and serum endocrine marker analysis. Expression of androgen receptor (AR), estrogen receptor (ER), Ki-67, CYP17, CYP19, and other biomarkers was evaluated in CTCs and/or FFPETs. Cox regression analysis stratified by number of prior therapies and type of therapy was used to evaluate biomarker associations with progression-free survival (PFS). Statistical comparisons were performed for treatment effect in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
